Empowering Early Discovery of Peptide Drugs and Peptide-Based Delivery Tools

DATE

September 12, 2024

TIME

8:00 a.m. PDT, 11:00 a.m. EDT, 16:00 BST, 17:00 CEST - Duration: 60 Minutes

Overview

Peptides exhibit a strong affinity for their targets, with high specificity and few side effects. Cyclic peptides constitute a significant portion of marketed peptide drugs. These cyclic peptides have a larger binding surface for protein targets and can exert a wider range of pharmacological actions through protein-protein interactions. Peptide therapeutic discovery is experiencing a resurgence, especially for challenging, historically “undruggable” targets. Cyclic peptides can form stable conformations through internal hydrogen bonds, which helps them resist enzymatic degradation in the body. The “chameleon effect” allows cyclic peptides to transition between several conformations, enhancing their absorption and intracellular penetration.

Recent advancements in peptide drug discovery include the evolution of mRNA display and peptide DNA-encoded library (DEL) technology for hit generation and selection, as well as novel cyclization techniques and their combinations for peptide conformational rigidity. These developments are crucial for achieving desired binding affinity and efficacy, thereby facilitating the development of potent and orally available peptide drugs.

Key Learning Objectives:

Recent advancements in medicinal chemistry to improve stability, selectivity, and therapeutic efficacy of cyclic peptides
Strategies to improve the stability of cyclic peptides
Strategies to improve the permeability of cyclic peptides
Understand differences in peptide screening platforms

Who Should Attend:

Researchers working on peptide/cyclic peptide discovery and undruggable targets
Researchers interested in strategies to improve ADME/DMPK properties of cyclic peptides
Researchers interested in lead optimization strategies for peptide drug discovery

Brought to you by:

Speakers

Dr. Yuqi Zhang,
Principal Scientist I,
WuXi TIDES Peptide Discovery

Rhys Taylor,
Associate Director of Peptide Discovery,
WuXi AppTec

Jianping Sun,
Study Director, DMPK,
WuXi AppTec

Kelly McSweeney
Contributing Editor,
C&EN Media Group

Registration

Forwarded this event? Clear the form

Email Address*

Salutation

First Name*

Last Name*

Company*

Job Title*

Address 1*

City*

State*

Zip / Post Code*

Country/Territory/Area*

Business Phone*

Which peptide discovery platform interests you the most?*

Do you need to optimize the DMPK properties of peptide drugs?*

Are you currently facing any specific challenges in peptide drug discovery that you need addressed?*

I would like to receive C&EN’s weekly newsletter with the latest in chemistry news

I would like to receive more information on products and services from the American Chemical Society

*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society (ACS Publications) and its sponsor via email. ACS takes your privacy seriously. For more information, please see the ACS Privacy Policy.

View On Demand Webinars